Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daxdilimab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Daxdilimab is a human monoclonal antibody that targets ILT7 (also known as LILRA4), a cell surface molecule specifically expressed on plasmacytoid dendritic cells (pDCs)[1][2][6]. By binding to ILT7, daxdilimab selectively depletes pDCs, which are key producers of type I interferon and play a central role in the pathogenesis of several autoimmune diseases[6][7]. The drug is administered via subcutaneous injection and is being developed for multiple autoimmune indications, including systemic lupus erythematosus (SLE), dermatomyositis, discoid lupus erythematosus, lupus nephritis, myositis, and alopecia areata[2][3][5]. Daxdilimab was originally developed by SBI Biotech and is currently being advanced by Horizon Therapeutics (formerly Viela Bio)[2].
- Brand names
- daxdilimab
- Other names
- anti-ILT7 antibodyanti-ILT-7 antibodyanti-ILT 7 antibody
02
Targets
LILRA4 (Leukocyte immunoglobulin-like receptor subfamily A member 4)
Beyond the preview
Go deeper on daxdilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daxdilimab.